Simbec Orion

Company Story:

Simbec-Orion was created in 2014 by the merger of two very experienced CROs: Simbec Research, a specialist CRO in Early Stage Clinical Development and Orion Clinical, the specialist CRO in Late Stage Clinical Development to create an international, full service, boutique CRO. The core expertise is in clinical pharmacology, oncology, rare diseases and areas of unmet medical need. The CRO has already delivered studies including > 5,200 patients in the last 5 years alone with 350 employees delivering international clinical trials across 4 continents in over 35 countries from supporting clinical development plans from Phase I-IV.


  • A full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies
  • Specialist expertise in oncology, rare and orphan diseases, respiratory, dermatology and infectious diseases & vaccines
  • In-depth experience of all drug types, dosage forms and delivery mechanisms
  • Access to patient populations across Europe and North America


Joint Project Title

Turkey’s first-ever phase-1 clinical trial of a targeted chemotherapy drug

Partnership by

🇹🇷 RS Research

🇬🇧 Simbec Orion

View Details

Company Info:

Establishment Date:

January 1, 2014

Number of Employees:



Drug development


Explore more companies:

Supported by